<DOC>
	<DOCNO>NCT00858299</DOCNO>
	<brief_summary>This study multicenter , prospective , interventional study . It control group . All participant receive 160 mg valsartan 8 week . Among , patient persistent proteinuria ( define proteinuria 1 g/g 8 week treatment valsartan ) receive 320 mg valsartan 16 week . Participants receive ACEI ARB previously titration period 4 week ( 80 mg 4 week , 160 mg 4 week , 320 mg 16 week ) . The investigator evaluate change urinary angiotensinogen excretion baseline , 8 week , 24 week .</brief_summary>
	<brief_title>The Change Urinary Angiotensinogen Excretion After Valsartan Treatment Patients With Persistent Proteinuria</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<criteria>Chronic kidney disease patient proteinuria 1 10 g/day , stable control blood pressure ( 100/60 mmHg 160/100 mmHg ) , stable renal function GFR â‰¥ 30 mL/min/ m2 , diabetes nondiabetes Uncontrolled diabetes ( define HbA1c &gt; 9.0 % ) Immunosuppressive treatment within 6 month Intractable edema Hyperkalemia ( &gt; 5.5 mEq/L ) Hypokalemia ( &lt; 3.5 mEq/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>proteinuria</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>renin-angiotensin system</keyword>
	<keyword>angiotensinogen</keyword>
</DOC>